<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01955681</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-OTW-XXX-2013/1</org_study_id>
    <nct_id>NCT01955681</nct_id>
  </id_info>
  <brief_title>A Retrospective, Non-interventional, Multicenter, Observational Chart Review Study to Explore the Clinical Benefits of Retreatment With TKI in the Real World.</brief_title>
  <acronym>SEQUENCE</acronym>
  <official_title>A Retrospective, Non-interventional Study to Evaluate EGFR-Tyrosine Kinase Inhibitor Retreatment in Patients With Locally Advanced or Metastatic EGFR Mutated NSCLC Who Previously Treated With EGFR-TKI as First-line Therapy and Chemotherapy as Second-line Therapy - SEQUENCE Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a retrospective, non-interventional, multicenter, observational chart review study to
      explore the clinical benefits of retreatment with TKI in the real world.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to retrospectively review the medical and chemotherapy records of 300
      patients with EGFR mutation positive adenocarcinoma NSCLC. Eligible patients are as follows:
      histologically or cytologically confirmed NSCLC, undergone EGFR-TKI retreatment sometime
      after the failure of the initial EGFR-TKI. After initial treatment, patients had been treated
      with chemotherapy and subsequently re-treated with EGFR-TKI will be identified. The target
      population will be derived from multicentre in Taiwan. The study aim is to evaluate clinical
      effect in re-administration of EGFR-TKI using retrospectively collected data from these
      eligible patients to provide valuable information.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The treatment duration of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor re-administration</measure>
    <time_frame>From the start of re-administration of EGFR-TKI to data cut-off date, assessed approximately up to 6 months.</time_frame>
    <description>The median duration of re-administration of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor will be summarized by days or months, if applicable. The range of this treatment duration will also be presented. All analyses will be performed on all eligible patients in this study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of progression-free survival for initial, second EGFR-TKI treatment and chemotherapy between two Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor treatments.</measure>
    <time_frame>From the start of administration of EGFR-TKI to data cut-off date, assessed approximately up to 6 months.</time_frame>
    <description>The outcome of progression-free survival will be presented with median values and associated 95% CIs by Kaplan-Meier curve. PFS is defined as the time interval (in weeks) from the start date of a given treatment to the date of disease progression or death, respectively, which one is observed first. Subjects who did not progress or die without a reported progression will be censored on the date of their last tumor assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of overall survival for initial, second EGFR-TKI treatment and chemotherapy between two Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor treatments.</measure>
    <time_frame>From the start of administration of EGFR-TKI to data cut-off date, assessed approximately up to 6 months.</time_frame>
    <description>The outcome of overall survival will be presented with median values and associated 95% CIs by Kaplan-Meier curve. OS is defined as the time interval (in weeks) from the beginning of treatment until the date when death or lost to follow up is observed. For those subjects who have not died or lost to follow-up, survival duration will be censored at the last date the subject was known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of response rate for initial, second EGFR-TKI treatment and chemotherapy between two Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor treatments.</measure>
    <time_frame>From the start of administration of EGFR-TKI to data cut-off date, assessed approximately up to 6 months.</time_frame>
    <description>The outcome about response rate and the proportion of response rate are estimated by all evaluable patients. The 95% exact confidence interval will be constructed around the rates. The best response during treatment sequences is determined in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of disease control rate for initial, second EGFR-TKI treatment and chemotherapy between two Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor treatments.</measure>
    <time_frame>From the start of administration of EGFR-TKI to data cut-off date, assessed approximately up to 6 months.</time_frame>
    <description>The outcome of disease control rate are estimated by all evaluable patients. The 95% exact confidence interval will be constructed around the rates. Disease Control Rate is defined as patients who are respond to treatment (including CR-complete respond, PR-partial respond or SD- Stable Disease).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Record treatment duration in the initial EGFR-TKI therapy and first time chemotherapy.</measure>
    <time_frame>Between the initial EGFR-TKI therapy and first time chemotherapy.</time_frame>
    <description>Treatment duration in the initial EGFR-TKI therapy and first time chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Record the reason(s) for treatment change for initial and re-administration of EGFR-TKI therapy and first time chemotherapy (second-line treatment).</measure>
    <time_frame>From the start of administration of EGFR-TKI to data cut-off date, assessed approximately up to 6 months.</time_frame>
    <description>Record the reason(s) for treatment change for initial and re-administration of EGFR-TKI therapy and first time chemotherapy (second-line treatment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Explore relationships between efficacy of EGFR-TKI initial and re-administration and patient characteristics or EGFR TKI treatment characteristics.</measure>
    <time_frame>EGFR-TKI initial and re-administration</time_frame>
    <description>Explore relationships between efficacy of EGFR-TKI initial and re-administration and patient characteristics (including demographics, histology, disease stage, sites of metastasis, ECOG PS) or EGFR TKI treatment characteristics (including EGFR mutation pattern, response to initial EGFR TKI or not, length of duration between first and second EGFR-TKI treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS), plasma CEA level and chemotherapy regimens ever used.</measure>
    <time_frame>between first time chemotherapy and EGFR-TKI re-administration</time_frame>
    <description>Explore overall survival (OS), plasma CEA level and chemotherapy regimens ever used between first time chemotherapy and EGFR-TKI re-administration (including the types and number of chemotherapy regimens, and treatment duration) for those patients who have the above data available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>image peer review to evaluate tumour size retrospectively in different sequences of treatment</measure>
    <time_frame>(1) initial and re-administration of EGFR-TKI therapy, (2) first time chemotherapy ever used (second-line treatment) after initial EGFR-TKI treatment.</time_frame>
    <description>If the images are available, conduct image peer review to evaluate tumour size retrospectively in different sequences of treatment: (1) initial and re-administration of EGFR-TKI therapy, (2) first time chemotherapy ever used (second-line treatment) after initial EGFR-TKI treatment. Peer review time point includes baseline, best response and progression of last image while stopping treatment at each treatment mentioned above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The reason(s) for the treatment change for initial and re-administration of EGFR-TKI therapy and first time chemotherapy (second-line treatment) after peer review</measure>
    <time_frame>Initial and re-administration of EGFR-TKI therapy and first time chemotherapy (second-line treatment) after peer review.</time_frame>
    <description>Evaluate the reason(s) for the treatment change for initial and re-administration of EGFR-TKI therapy and first time chemotherapy (second-line treatment) after peer review and compare the difference of reason(s) for the treatment change between initiatial evaluation and after peer review.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Locally Advanced or Metastatic EGFR Mutated NSCLC.</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with locally advanced or metastatic Epidermal Growth Factor Receptor mutated
        Non-small-cell Lung Cancer who Previously Treated with Epidermal Growth Factor Receptor
        Tyrosine Kinase Inhibitor as First-line therapy and chemotherapy as second-line Therapy -
        SEQUENCE study
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients diagnosed with advanced adenocarcinoma or positive result of thyroid
             transcription factor 1 NSCLC

          2. Positive Epidermal Growth Factor Receptor mutation result with sensitive mutation

          3. Female or male aged â‰§20 years

          4. Patients treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor and
             subsequently treated with chemotherapy before re-administration of Epidermal Growth
             Factor Receptor Tyrosine Kinase Inhibitor. Exclusion Criteria:

        1. Patients with EGFR mutation status of positive exon 20 T790M mutation only. 2. Patients
        who are confirmed of squamous type NSCLC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>150 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuh-Min Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Veterans General Hospital, Taiwan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gee-Chen Chang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Veterans General Hospital -Taichung</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chong-Jen Yu</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cheng-Ta Yang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Te-Chun Hsia</last_name>
    <role>Principal Investigator</role>
    <affiliation>China Medical University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Meng-Chih Lin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang-Gung Memorial Hospital Kaohsiung</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ying-Huang Tsai</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang-Gung Memorial Hospital ChiaYi</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chiayi</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tao Yuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1850&amp;filename=CSR_NIS-OTW-XXX-2013_1.pdf</url>
    <description>CSR_Synopsis_NIS-OTW-XXX-2013_1</description>
  </link>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2013</study_first_submitted>
  <study_first_submitted_qc>September 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2013</study_first_posted>
  <last_update_submitted>November 3, 2015</last_update_submitted>
  <last_update_submitted_qc>November 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor retrement.</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

